Inari Medical Closes Acquisition of LimFlow
15 Novembre 2023 - 10:05PM
Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device
company with a mission to treat and transform the lives of patients
suffering from venous and other diseases, today announced the close
of its acquisition of LimFlow S.A., a privately-held pioneer in
limb salvage for patients with chronic limb-threatening ischemia
(CLTI).
“The close of the LimFlow acquisition allows us to begin to
integrate this exciting technology that is offering new hope to
patients suffering from CLTI,” said Drew Hykes, CEO of Inari.
“LimFlow addresses one of the most significant unmet needs in all
of vascular medicine, is closely aligned with our mission and adds
another highly differentiated growth platform into our
portfolio.”
On November 1, Inari announced a definitive agreement to acquire
LimFlow, S.A. for a total upfront consideration of $250 million
paid in cash upon closing. Contingent consideration of up to $165
million in additional cash payments are subject to the achievement
of certain commercial and reimbursement milestones and will be paid
out between 2025 and 2027. Inari funded the acquisition at close
from existing cash resources.
About Inari Medical, Inc.Patients first. No
small plans. Take care of each other. These are the guiding
principles that form the ethos of Inari Medical. We are committed
to improving lives in extraordinary ways by creating innovative
solutions for both unmet and underrecognized health needs. In
addition to our purpose-built products, we leverage our
capabilities in education, clinical research, and program
development to improve patient outcomes. We are passionate about
our mission to establish our treatments as the standard of care for
venous thromboembolism and beyond. We are just getting started.
Forward Looking StatementsStatements in this
press release may contain “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995
that are subject to substantial risks and uncertainties.
Forward-looking statements contained in this press release may be
identified by the use of words such as “may,” “will,” “should,”
“expect,” “plan,” “anticipate,” “could,” “intend,” “target,”
“project,” “contemplate,” “believe,” “estimate,” “predict,”
“potential” or “continue” or the negative of these terms or other
similar expressions. Forward-looking statements include, among
others, potential strategic benefits of the LimFlow acquisition,
and are based on Inari’s current expectations, forecasts, and
assumptions, are subject to inherent uncertainties, risks and
assumptions that are difficult to predict, and actual outcomes and
results could differ materially due to a number of factors. These
and other risks and uncertainties include those described more
fully in the section titled “Risk Factors” and “Management’s
Discussion and Analysis of Financial Condition and Results of
Operation” and elsewhere in its Annual Report on Form 10-K for the
period ended December 31, 2022, and in its other reports filed with
the U.S. Securities and Exchange Commission. Forward-looking
statements contained in this announcement are based on information
available to Inari as of the date hereof and are made only as of
the date of this release. Inari undertakes no obligation to update
such information except as required under applicable law. These
forward-looking statements should not be relied upon as
representing Inari’s views as of any date subsequent to the date of
this press release. In light of the foregoing, investors are urged
not to rely on any forward-looking statement in reaching any
conclusion or making any investment decision about any securities
of Inari.
Investor Contact:John Hsu, CFAVP, Investor
Relations949-658-3889IR@inarimedical.com
Inari Medical (NASDAQ:NARI)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Inari Medical (NASDAQ:NARI)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024